COVID-19: лечение и профилактика
Zurück
Furthermore, by the 27th of February, the results of 42 clinical trials, including approximately 15,000 patients (both registered and unregistered studies) have been subjected to a meta-analysis after exclusion of biasing factors. It was found that 83%
showed improvements with early treatment, 51% improved during late-stage treatment, and there was an 89% prevention of onset rate noted. This confirms the usefulness of ivermectin. Since it is a meta-analysis based on 42 test results, it is estimated that the probability of this comprehensive judgment being a mistake is as low as 1 in 4 trillion. In addition, two separate meta-analyses also showed the usefulness of ivermectin and their conclusions were presented to the WHO and the
US FDA with
a request for an expansion of the indication of ivermectin in the treatment of COVID-19.
Global trends in clinical studies of ivermectin in COVID-1...
